WO1997046669A9 - Mammiferes transgeniques avec suppression de l'expression de l'amyline - Google Patents
Mammiferes transgeniques avec suppression de l'expression de l'amylineInfo
- Publication number
- WO1997046669A9 WO1997046669A9 PCT/US1997/009887 US9709887W WO9746669A9 WO 1997046669 A9 WO1997046669 A9 WO 1997046669A9 US 9709887 W US9709887 W US 9709887W WO 9746669 A9 WO9746669 A9 WO 9746669A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amylin
- sequence
- gene
- glucose
- knockout
- Prior art date
Links
- 102000036849 Islet amyloid polypeptide Human genes 0.000 title claims abstract description 210
- 108010041872 Islet amyloid polypeptide Proteins 0.000 title claims abstract description 210
- 230000014509 gene expression Effects 0.000 title claims description 29
- 241000124008 Mammalia Species 0.000 title description 24
- 230000000694 effects Effects 0.000 claims abstract description 45
- 230000001629 suppression Effects 0.000 claims abstract description 17
- 239000003550 marker Substances 0.000 claims description 28
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 24
- 238000003780 insertion Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 241000283984 Rodentia Species 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 7
- 230000003247 decreasing Effects 0.000 claims description 7
- 229960004927 neomycin Drugs 0.000 claims description 6
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 238000010348 incorporation Methods 0.000 claims description 4
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- 230000002759 chromosomal Effects 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 102
- 239000008103 glucose Substances 0.000 description 63
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 62
- 102000004877 Insulin Human genes 0.000 description 51
- 108090001061 Insulin Proteins 0.000 description 51
- 210000004027 cells Anatomy 0.000 description 44
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 37
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 31
- 210000002381 Plasma Anatomy 0.000 description 29
- 241000700159 Rattus Species 0.000 description 21
- 206010012601 Diabetes mellitus Diseases 0.000 description 18
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 14
- 229940096919 Glycogen Drugs 0.000 description 14
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 14
- 229920002527 Glycogen Polymers 0.000 description 14
- DNKYDHSONDSTNJ-XJVRLEFXSA-N CHEMBL1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 description 12
- 108090000932 Calcitonin gene-related peptide Proteins 0.000 description 12
- 102000004414 Calcitonin gene-related peptide Human genes 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 230000003042 antagnostic Effects 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 230000030136 gastric emptying Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 8
- 229940088598 Enzyme Drugs 0.000 description 7
- 210000003205 Muscles Anatomy 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 108091005508 amylin receptors Proteins 0.000 description 7
- 230000003115 biocidal Effects 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108060001064 Calcitonin Proteins 0.000 description 6
- 102400000113 Calcitonin Human genes 0.000 description 6
- 229920002676 Complementary DNA Polymers 0.000 description 6
- 210000004185 Liver Anatomy 0.000 description 6
- 102100000775 REN Human genes 0.000 description 6
- 108090000783 Renin Proteins 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000002440 hepatic Effects 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 108091007521 restriction endonucleases Proteins 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- 229960004015 Calcitonin Drugs 0.000 description 5
- 102100003818 GCG Human genes 0.000 description 5
- 101710042131 GCG Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000020828 fasting Nutrition 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102100013472 CCK Human genes 0.000 description 4
- 229940107137 Cholecystokinin Drugs 0.000 description 4
- 108010048926 Cholecystokinin Proteins 0.000 description 4
- 229960004666 Glucagon Drugs 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 206010022489 Insulin resistance Diseases 0.000 description 4
- 230000036740 Metabolism Effects 0.000 description 4
- 210000000496 Pancreas Anatomy 0.000 description 4
- 210000002784 Stomach Anatomy 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035786 metabolism Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000000268 renotropic Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 240000003960 Ehretia acuminata Species 0.000 description 3
- 235000009300 Ehretia acuminata Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108020004999 Messenger RNA Proteins 0.000 description 3
- 101700059663 PGK1 Proteins 0.000 description 3
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002257 embryonic structures Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229920002106 messenger RNA Polymers 0.000 description 3
- 230000002503 metabolic Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 230000000291 postprandial Effects 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- 230000002797 proteolythic Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 229950006323 Angiotensin ii Drugs 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 2
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229920000665 Exon Polymers 0.000 description 2
- 210000003414 Extremities Anatomy 0.000 description 2
- 102100007572 GRP Human genes 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 229940090044 Injection Drugs 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000002997 Osteoclasts Anatomy 0.000 description 2
- 102100013410 PGK1 Human genes 0.000 description 2
- 102100005499 PTPRC Human genes 0.000 description 2
- 101700059076 PTPRC Proteins 0.000 description 2
- 229960001052 Streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 210000004291 Uterus Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 230000000994 depressed Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000004116 glycogenolysis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000002148 osteoclast Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029054 response to nutrient Effects 0.000 description 2
- 230000000580 secretagogue Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000000261 vasodilator Effects 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 241000867477 Amara Species 0.000 description 1
- 101710002767 BACOVA_02645 Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 210000002459 Blastocyst Anatomy 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N Bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 101700017623 CALCA Proteins 0.000 description 1
- 102000033175 CALCA Human genes 0.000 description 1
- 102100017603 CALCR Human genes 0.000 description 1
- 101700041770 CALCR Proteins 0.000 description 1
- 108010001789 Calcitonin Receptors Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007541 Cardiac disease Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108009000300 Cori Cycle Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 102000019460 EC 4.6.1.1 Human genes 0.000 description 1
- 108060000200 EC 4.6.1.1 Proteins 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 1
- 101700043311 GGTA1 Proteins 0.000 description 1
- 102100018365 GGTA1 Human genes 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N Gastrin-ReleasingPeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 210000002816 Gills Anatomy 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229940045189 Glucose-6-Phosphate Drugs 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N Glucose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 229940045644 Human calcitonin Drugs 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010022498 Insulinoma Diseases 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N L-Histidyl-L-seryl-L-a-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-a-glutamylglycyl -L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leu Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 238000006968 MacDonald synthesis reaction Methods 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 210000003593 Megakaryocytes Anatomy 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 108010065084 Phosphorylase a Proteins 0.000 description 1
- 240000000129 Piper nigrum Species 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 101710023382 S100A12 Proteins 0.000 description 1
- 102100001186 SCT Human genes 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 229960002101 Secretin Drugs 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010026080 Somatomedins Proteins 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 208000001608 Teratocarcinoma Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002862 amidating Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000001195 anabolic Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 230000001925 catabolic Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 101710019483 ebgA Proteins 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 230000000763 evoked Effects 0.000 description 1
- 230000032686 female pregnancy Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002039 glucoregulatory Effects 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 101500011263 human Calcitonin Proteins 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- 230000001969 hypertrophic Effects 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003040 nociceptive Effects 0.000 description 1
- 230000036963 noncompetitive Effects 0.000 description 1
- 230000001019 normoglycemic Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229950002350 secretin human Drugs 0.000 description 1
- 108010040171 secretin releasing peptide Proteins 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- This invention relates to mammals in which the expression of the amylin gene has been suppressed. More specifically, the invention concerns transgenic mammals with decreased or completely suppressed expression of the endogenous amylin gene.
- Amylin is a 37 amino acid protein hormone. It was isolated, purified and chemically characterized as the major component of amyloid deposits in the islets of pancreases of deceased human Type 2 diabetics (Cooper et al . , Proc . Natl . Acad. Sci .
- amylin is the subject of United States Patent No. 5,367,052, issued November 22, 1995.
- amylin has been shown to be deficient and combined replacement with insulin has been proposed as a preferred treatment over insulin alone in all forms of diabetes.
- the use of amylin and other amylin agonists for the treatment of diabetes mellitus is the subject of United States Patent No. 5,175,145, issued December 29, 1992.
- Pharmaceutical compositions containing amylin and amylin plus insulin are described in United States Patent No. 5,124,314, issued June 23, 1992.
- amylin action has been said to mimic key features of Type 2 diabetes and amylin blockade has been proposed as a novel therapeutic strategy. It has been disclosed in United States Patent No. 5,266,561, issued November 30, 1993, that amylin causes reduction in both basal and insulin-stimulated incorporation of labeled glucose into glycogen in skeletal muscle. The latter effect was also disclosed to be shared by calcitonin gene related peptide (CGRP) (see also Leighton and Cooper, Nature, 335:632-635 (1988)) . Amylin and CGRP were approximately equipotent, showing marked activity at 1 to 10 nM.
- CGRP calcitonin gene related peptide
- Amylin is also reported to reduce insulin-stimulated uptake of glucose into skeletal muscle and reduce glycogen content (Young et al . , Amer. J. Physiol . , 259:457-46-1 (1990) ) .
- the treatment of Type 2 diabetes and insulin resistance with amylin antagonists is disclosed.
- Amylin reportedly may be one member of a family of related peptides which includes CGRP, insulin, insulin- like growth factors and the relaxins and which share common genetic heritage (Cooper et al . , Prog. Growth Factor Research, 1:99-105 (1989)).
- the two peptides calcitonin and CGRP-1 share common parentage in the calcitonin gene where alternative processing of the primary mRNA transcript leads to the generation of the two distinct peptides, which share only limited sequence homology (about 30%) (Amara et al . , Science, 229:1094-1097 (1985) ) .
- amylin gene sequence is typical for a secreted messenger protein, with the mRNA coding a prepro- peptide with processing sites for production of the secreted protein within the Golgi or secretary granules .
- Amylin is mainly co- localized with insulin in beta cell granules and may share the proteolytic processing enzymes that generate insulin from pro-insulin.
- Amylin is primarily synthesized in pancreatic beta cells and is secreted in response to nutrient stimuli such as glucose and arginine .
- nutrient stimuli such as glucose and arginine .
- Studies with cloned beta- cell tumor lines (Moore et al . , Biochem . Biophys . Res . Commun . , 179(1) (1991)), isolated islets (Kanatsuka et al. , FEBS Letts . , 259(1), 199-201 (1989)) and perfused rat pancreases (Ogawa et al . , J " . Clin . Invest . , 85:973-976
- amylin insulin ratio of the secreted proteins varies between preparations from about 0.01 to 0.4, but appears not to vary much with acute stimuli in any one preparation.
- the amylin: insulin ratio can progressively increase (Gedulin et al . , Biochem . Biophys . Res . Commun . , 180 (1) :782-789 (1991)).
- amylin and insulin are not always secreted in a constant ratio.
- amylin reduces glycogen synthase activity, promotes conversion of glycogen phosphorylase from the inactive b form to the active a form, promotes net loss of glycogen (in the presence or absence of insulin) , increases glucose-6-phosphate levels, and can increase lactate output (see, e.g.. Deems et. al . , Biochem . Biophys .
- Amylin like epinephrine, appears not to affect glucose transport per se (e.g. , Pittner et al . , FEBS Letts . , 365 (1) :98-100 (1995)).
- Studies of amylin and insulin dose-response relations show that amylin acts as a non- competitive or functional antagonist of insulin in skeletal muscle (Young et al . , Am. J. Physiol . , 263(2) :E274- E281 (1992) ) .
- amylin interferes with insulin binding to its receptors, or the subsequent activation of insulin receptor tyrosine kinase (Follett et al. , Clinical Research, 39(1) :39A (1991)); Koopmans et al. , Diabetologia, 34:218-224 (1991)).
- the actions of amylin on skeletal muscle resemble those of adrenaline (epinephrine).
- adrenaline's actions are believed to be mediated largely by cAMP
- some workers have concluded that amylin' s actions are not mediated by cAMP (see Deems et al . , Biochem . Biophys . Res . Commun . , 181(1)-
- amylin acts through recep- tors present in plasma membranes. It has been reported that amylin works in skeletal muscle via a receptor- mediated mechanism that promotes glycogenolysis, by activating the rate-limiting enzyme for glycogen breakdown, phosphorylase a (Young et al . , FEBS Letts . , 281:149- 151 (1991) ) . Studies of amylin and CGRP, and the effect of selective antagonists, suggest that amylin acts via its own receptor (Beaumont et al . , Br. J. Pharmacol . , 115(5) :- 713-715 (1995); Wang et al ⁇ , FEBS Letts .
- amylin may act primarily at CGRP receptors (e.g. , Chantry et al. , Biochem . J. , 277:139-143 (1991)); Galeazza et al . , Peptides, 12:585-591 (1991)); Zhu et al . , Biochem . Biophy- s . Res . Commun . , Ill (2) :771-776 (1991)).
- CGRP receptors e.g. , Chantry et al. , Biochem . J. , 277:139-143 (1991)
- Galeazza et al . Peptides, 12:585-591 (1991)
- Zhu et al . Biochem . Biophy- s . Res . Commun . , Ill (2) :771-776 (1991)
- amylin has marked effects on hepatic fuel metabolism in vivo, there is no general agreement as to what amylin actions are seen in isolated hepatocytes or perfused liver.
- the available data do not support the idea that amylin promotes hepatic glycogenolysis, i.e., it does not act like glucagon (e.g. , Stephens et al . , Diabetes, 40:395-400 (1991); Gomez-Foix et al . , Biochem J. , 276:607-610 (1991)).
- amylin may act on the liver to promote conversion of lactate to glycogen and to enhance the amount of glucose able to be liberated by glucagon (see Roden et al . , Diabetologia, 35:116-120 (1992)) .
- amylin could act as an anabolic partner to insulin in liver, in contrast to its catabolic action in muscle.
- amylin In fat cells, contrary to its adrenalin-like action in muscle, amylin has no detectable actions on insulin-stimulated glucose uptake, incorporation of glucose into triglyceride, C0 2 production (Cooper et al . , Proc . Na tl . Acad . Sci . , 85 : 1163 - 1166 (1988)) epinephrine- stimulated lipolysis, or insulin-inhibition of lipolysis (Lupien and Young, "Diabetes Nutrition and Metabolism - Clinical and Experimental," Vol. 6(1), pages 1318 (February 1993)). Amylin thus exerts tissue-specific effects, with direct action on skeletal muscle, marked indirect (via supply of substrate) and perhaps direct effects on liver, while adipocytes appear "blind" to the presence or absence of amylin.
- amylin can have marked effects on secretion of insulin.
- isolated islets Ohsawa et al . , Biochem . Biophys . Res . Commun . , 160 (2) :961-967 (1989)
- pancreas in the perfused pancreas
- rat in the intact rat
- amylin inhibits insulin secretion.
- amylin infusions cause "insulin resistance", both by reducing peripheral glucose disposal, and by limiting insulin-mediated suppression of hepatic glucose output (e.g. , Frontoni et al . , Diabetes, 40:568- 573 (1991)); Koopmans et al . , Diabetologia, 34:218-224 (1991) ) .
- amylin injections stimulated rises in plasma lactate from about 0.5 to 1.5 mM followed by a prolonged increase in plasma glucose levels from about 6 to 11 mM. These effects were observed for both intravenous and subcutaneous injections (Young et al . , FEBS Letts . , 281 (1, 2) : 149- 151 (1991) ) .
- the effects of amylin in fed animals differ quantitatively from its effects in fasted animals. In fed rats, with presumably normal liver glycogen stores, amylin causes a more pronounced and prolonged rise in plasma lactate; however, there is only a modest rise in plasma glucose.
- amylin promotes the "return limb" of the Cori cycle, i.e., muscle glycogen via breakdown to lactate provides substrate for hepatic gluconeogenesis and glycogen production and probably triglyceride synthesis.
- Insulin drives the forward limb, i.e., uptake of glucose into muscle and production of muscle glycogen.
- Insulin and amylin can thus be seen as partners in regulating the "indirect” pathway of postprandial hepatic glycogen repletion.
- "Insulin resistance" in muscle and liver may be under normal, physiologic regulation by amylin.
- Amylin or amylin agonists potently inhibit gastric emptying in rats (Young et al . , Diabetologia 38 (6) : 642-648 (1995)), dogs (Brown et al . , Diabetes 43(Suppl 1) :172A (1994)) and humans (Macdonald et al . , Diabetologia 38 (Suppl 1) :A32 (abstract 118) (1995) ) . Because gastric emptying is accelerated in amylin-defi- cient type 1 diabetic BB rats (Young et al . , Diabetologia , supra ; Nowak et al . , J. Lab . Clin .
- Control of nutrient release from the stomach is becoming recognized as an important component of overall fuel homeostasis.
- energy release from the stomach was remarkably constant at ⁇ 2 kcal/min (Brener et al . , Gastroenterology, 85(l):76-82 (1983)), equivalent to -500 mg glucose/min.
- This release rate is about the same as the rate of glucose disposal that insulin-sensitive individuals can attain at their peak plasma insulin concentrations (1 nM) (Young et al . , Am . J. Physiol . , 254 (2 Pt 1) :E231-236 (1988)).
- the rate at which carbohydrate is released from the stomach and absorbed is normally matched to the rate at which it can be metabolized.
- Several feedback loops may control nutrient efflux from the stomach.
- Peptides that are candidates as participants in such control loops should (1) change in response to meals, and (2) potently modulate gastric emptying.
- Peptides known to inhibit gastric emptying are limited to amylin, cholecystokinin (CCK) , glucagon-like peptide-1 (GLP-1) , secretin and gastrin releasing pep- tide/bombesin (GRP) .
- GRP does not change with meals. Secretin is secreted in response to acid (but not nutrients) entering the duodenum.
- amylin is the more potent (Young et al . , Metabolism Clinical and Experimental 45(1) :l-3 (1996)), and it appears that amylin may be a major regulator of carbohydrate absorption, at least in rodents (Young et al . , Biochemical Society Transactions 23 (2) :325-331 (1995) ) .
- Non-metabolic actions of amylin include vasodilator effects which may be mediated by interaction with CGRP vascular receptors .
- Reported in vivo tests suggest that amylin is at least about 100 to 1000 times less potent than CGRP as a vasodilator (Brain et al . , Eur. J. Pharmacol . , 183:2221 (1990); Wang et al . , FEBS Letts . , 291:195-198 (1991)).
- the effect of amylin on regional hemodynamic actions, including renal blood flow, in conscious rats was recently reported (Gardiner et al . , Diabetes, 40:948-951 (1991)).
- Amylin has also been reported to have effects both on isolated osteoclasts where it caused cell quies- cence, and in vivo where it was reported to lower plasma calcium by up to 20% in rats, in rabbits, and in humans with Paget's disease (see, e.g., Zaidi et al . , Trends in Endocrinol . and Me tab . , 4:255-259 (1993). From the avail- able data, amylin seems to be 10 to 30 times less potent than human calcitonin for these actions.
- amylin receptor antagonists may be used to alter glucoregulation.
- 8 ⁇ 37 CGRP is a demonstrated amylin blocker in vitro and in vivo (Wang et al . , Biochem. Biophys . Res . Commun . , 181 (3) : 1288-1293 (1991)), and was found to alter glucoregulation following an arginine infusion in fed rats (Young et al . , Mol . Cell . Endocrinol - ., 84:R1-R5 (1992)).
- the initial increase in glucose concentration is attributed to arginine-stimulated gluca- gon secretion from islet alpha cells; the subsequent restoration of basal glucose is attributed to insulin action along with changes in other glucoregulatory hor- mones.
- the action of amylin is blocked by preinfusi- on of 8 ⁇ 37 hCGRP, the initial glucose increase is not significantly different, but there is a subsequent fall in glucose concentration to well below the basal level, which is restored only after some 80 minutes.
- glucoregul- ation following this challenge with an islet secretagogue was reportedly altered by infusion of an amylin receptor antagonist.
- amylin markedly increases plasma renin activity in intact rats when given subcutaneously in a manner that avoids any disturbance of blood pressure. This latter point is important because lowered blood pressure is a strong stimulus to renin release.
- Amylin antagonists such as amylin receptor antagonists, including those selective for amylin recep- tors compared to CGRP and/or calcitonin receptors, can be used to block the amylin-evoked rise of plasma renin activity.
- amylin antagonists to favorably modulate insulin resistance and other common metabolic disorders frequently associated with hypertension and cardiac disease provides a particularly desirable therapeutic profile.
- amylin antagonists to treat renin-related disorders is described in United States Patent No. 5,376,638, issued December 27, 1994.
- the values for fasting and post-prandial insulin are 20 to 50pM, and 100 to 300 pM respectively in healthy people, with perhaps 3 -to 4-fold higher levels in insulin-resistant people.
- amylin levels are at or below the levels of detection and do not rise in response to glucose (Koda et al . , The Lancet, 339:1179-1180 (1992)).
- basal amylin levels have been reported from 30 to 100 pM, while values up to 600 pM have been measured in certain insulin-resistant, diabetic strains of rodents (e.g. , Huang et al . , Hypertension, 19:1-101-1-109 (1991); Gill et al . , Life Sciences, 48:703- 710 (1991) ) .
- Type 1 diabetes patients with Type 1 diabetes, in addition to a lack of insulin, are reported to have marked amylin defi- ciency.
- data show that amylin expression and secretion by pancreatic beta cells is absent or well below normal in Type 1 diabetes.
- amylin secretion and gene expression are depressed (Cooper et al . , Diabetes, 497-500 (1991) ; Ogawa et al . , J " . Clin . Invest . , 85:973-976 (1990)).
- transgenic mammals have been produced which have altered levels of expression of certain genes .
- One class of these mammals are the so-called transgenic mammals. These mammals have a novel gene or genes introduced into their genome. Another class of these mammals is the so- called “knockout" mammals, wherein expression of an endogenous gene has been suppressed thorough genetic manipulation.
- a variety of transgenic mammals have been developed. For example, United States Patent No. 4,736,8- 66 issued April 12, 1988 describes a mouse containing a transgene encoding an oncogene . United States Patent No. 5,175,384, issued December 29, 1992, describes a transgenic mouse deficient in mature T cells. United States Patent No.
- Pfeffer et al . , Cell, 73:457-467 (1993) report mice in which the gene encoding the tumor necrosis factor receptor p55 has been suppressed. The mice showed a decreased response to tumor necrosis factor signaling.
- Fung-Leung et al . , Cell, 65:443-449 (1991) report knockout mice lacking expression of the gene encoding CD8.
- Kishira et al. , Cell, 74:143-56 (1993) report the generation of a mouse with a mutation in exon 6 on CD45. This mouse reportedly does not express CD45.
- a Fmrl knockout mouse has been proposed by the Dutch-Belgian Fragile X Consortium as a model to study fragile X mental retardation (Cell, 78:23-33 (1994)).
- Di Simone et a Transplantation, 61:13-19 (1996), report a alpha-1 , 3 -galactosyltrans- ferase knockout mouse and suggest that it may have implications for xenotransplantation.
- Thomas, Am. J. Cell. Mol . Biol . , 12:461-463 (1995) discusses knockout mice and the phenotypes resulting from various mutations.
- an animal model for amylin deficiency alone is also useful for screening and evaluating compounds useful in the treatment of amylin- related disorders, including diabetes. Accordingly, it is an object of this invention to provide mammals in which a gene involved in the production of amylin has been sup- pressed.
- the present invention provides an animal, preferably a mouse, and its progeny having a suppressed level of expression of the gene encoding amylin.
- the gene may be suppressed by inserting into the relevant portion of the genome of the mouse or other animal a nucleic acid sequence comprising, for example, a portion of an exon of the amylin-encoding sequence of the animal linked to a marker sequence.
- the sequence into which the nucleic acid sequence is inserted may be any sequence which allows expression of amylin to be blocked, for example, a sequence which codes for preproamylin, proamylin or amylin.
- the marker sequence may be an antibiotic resistance gene, for example, a neomycin resistance gene.
- the invention provides a mouse or other animal and its progeny wherein expression of the gene encoding amylin is suppressed.
- the invention further provides mice and other animals with a decreased level of amylin expression.
- the invention provides a method of screening a compound for amylin activity comprising administering the compound to a mouse or other animal with a suppressed level of amylin expression, and assaying the mouse or other animal for amylin activity.
- FIGURE 1 depicts a mouse amylin genomic sequence (LAMBDA M-amylin 14) isolated from a mouse Balb/c lambda FIXII library using a human amylin cDNA probe in low stringency hybridization.
- LAMBDA M-amylin 14 isolated from a mouse Balb/c lambda FIXII library using a human amylin cDNA probe in low stringency hybridization.
- FIGURE 2 depicts a 3.46 kbp Hindlll-Xbal fragment of a subclone from LAMBDA M-amylin-14 (pHX) .
- FIGURE 3 depicts the sequence resulting from removal of the amylin encoding sequence from pHX (by deleting an 890-base pair sequence by restriction digestion with Sphl and BamHI) .
- FIGURE 4 depicts the knockout construct used to suppress expression of amylin.
- FIGURE 5 depicts plasma glucose levels (Fig. 5A) and plasma insulin levels (Fig. 5B) in male and female amylin knockout mice (solid circles) and wild type mice (open circles) . Values are plus or minus the standard error of the mean. *** P ⁇ 0.001, ** P ⁇ 0.01, * P ⁇ 0.05, two-tailed unpaired t-test.
- FIGURE 6 depicts plasma glucose levels (Fig. 6A) and plasma insulin levels (Fig. 6B) in male and female amylin knockout mice (solid circles) and wild type mice (open circles) , during OGTT. Values are plus or minus the standard error of the mean. *** P ⁇ 0.001, ** P ⁇ 0.01, * P ⁇ 0.05, two-tailed unpaired t-test.
- FIGURE 7 depicts plasma glucose levels (Fig. 7A) and plasma insulin levels (Fig. 7B) in male and female amylin knockout mice (solid circles) and wild type mice (open circles) , during IVGTT. Values are plus or minus the standard error of the mean. *** P ⁇ 0.001, ** P ⁇ 0.01, * P ⁇ 0.05, two-tailed unpaired t-test.
- FIGURE 8 depicts approximated daily food intake (Fig. 8A) and weight gain Fig. 8B) in male and female amylin knockout mice (solid circles) and wild type mice (open circles) . Values are plus or minus the standard error of the mean. *** P ⁇ 0.001, ** P ⁇ 0.01, * P ⁇ 0.05, two-tailed unpaired t-test.
- FIGURE 9 depicts the duration of paw licking in the first (0-5 minutes) and second phase (10-30 minutes) following subcutaneous injection of formalin in amylin knockout (mutant) mice and wild type mice.
- * P 0.027, Mann-Whitney U-test.
- knockout refers to a partial or complete suppression of the expression of at least a portion of a protein encoded by an endogenous DNA sequence in a cell.
- the present invention provides knockout mammals in which the expression of the protein amylin is suppressed.
- a knockout construct nucleic acid sequence may comprise a full or partial sequence of one or more exons and/or introns of the gene to be suppressed and/or a full or partial promotor sequence of the gene to be suppressed.
- knockout construct refers to a nucleic acid sequence that is designed to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell, and is typically comprised of (1) DNA from some portion of the amylin gene; and (2) a marker sequence used to detect the presence of the knockout nucleic acid sequence in the cell.
- amylin gene refers to any DNA sequence relating to the production of amylin, including but not limited to the prepro-amylin sequence, the pro-amylin sequence, and the amylin sequence currently found on chromosome 12.
- marker se- quence refers to a nucleic acid sequence that is (1) used as a part of a knockout nucleic acid construct to disrupt the expression of the amylin gene; and (2) used as a means to identify those cells that have incorporated the knock- out construct into the genome.
- the marker sequence may be any sequence which serves these purposes, although typically it will be a sequence encoding a protein that confers a detectable trait on the cell, such as an antibiotic resistance gene or an assayable enzyme not typically found in the cell. If the marker sequence encodes a protein, the marker sequence will also typically contain a promotor which regulates its expression.
- the knockout construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to prevent or interrupt transcription of the native DNA sequence. Such insertion usually occurs by homologous recombination. Thus, regions of the knockout construct that are homologous to endogenous DNA sequences hybridize to each other when the knockout construct is inserted into the cell and recombine so that the knockout construct is incorporated into the corresponding position of the endogenous DNA.
- the knockout construct is inserted into an embryonic stem cell and is integrated into the embryonic stem cell genomic DNA, usually by the process of homologous recombination. This embryonic stem cell is then injected into, and integrates with, the deve1oping embryo .
- amylin refers to the 37-amino acid protein hormone having a disulphide bridge between the cysteine residues at positions two and seven and a C- terminal NH 2 group. See United States Patent No. 5,367,05- 2, issued November 22, 1994.
- progeny refers to any and all future generations derived and descending from a particular mammal, i.e., a mammal containing a knockout construct inserted in to its genomic DNA. Thus, progeny of any successive generation are included herein such that the progeny, the FI, F2 and F3 generations and so on indefinitely are included in this definition.
- amylin activity refers to a biologi- cal activity of amylin, for example, activity in inhibiting insulin-stimulated glycogen synthesis in isolated soleus muscle, or delaying gastric emptying in vivo.
- the DNA to be used in the knockout construct will be a portion or all of one or more amylin exon and/or intron regions, with or without a promotor region.
- the DNA will be at least about 1 kil- obase pair (kbp) in length and preferably 3-4 kbp or more in length, more preferably 5-14 kbp or more in length and, specifically, is as long or as short as needed to provide for a sufficient complementary sequence for hybridization when the knockout construct is introduced into the genomic DNA of the embryonic stem cell.
- the DNA to be used in preparing the knockout construct contained exon three of the amylin gene.
- the DNA sequence to be used to knock out the amylin gene can be obtained using various art known methods such as those described by Sambrook et al . , Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory PRess, Cold Spring Harbor, NY (1989) . Such methods include, for example, screening a genomic library with a cDNA probe encoding at least a portion of the amylin gene to obtain at least a portion of the genomic sequence for amylin.
- Example 1 describes the use of a human amylin cDNA probe corresponding to a 300 bp BamHI fragment of a cDNA clone (described Mosselman, et al . , FEBS Lett .
- the DNA sequence encoding the knockout construct must be generated in sufficient quantity for genetic manipulation and insertion into embryonic stem cells.
- Amplification may be conducted by known methods, including (1) placing the sequence into a suitable vector and transforming bacterial or other cells which can rapidly amplify the vector; (2) by polymerase chain reaction (PCR) amplification; or (3) by synthesis with a DNA synthesizer.
- PCR polymerase chain reaction
- the DNA sequence to be used in producing the knockout construct is digested with a particular restriction enzyme selected to cut at a location (s) such that a new DNA sequence encoding a marker sequence can be inserted in the proper position within this DNA sequence.
- the proper position for marker sequence insertion is that which will serve to prevent expression of the native amylin gene. This position will depend on various fac- tors, such as the restriction sites in the sequence to be cut, and whether an exon sequence or a promotor sequence, or both ,are to be interrupted (i.e. , the precise location of insertion necessary to inhibit promotor function or to inhibit synthesis of the native exon) .
- the enzyme selected for cutting the DNA will generate a longer arm and a shorter arm, where the shorter arm is about 300 base pairs (bp) .
- the shorter arm is about 300 base pairs (bp) .
- the genomic amylin DNA is cut with appropriate restriction endonucleases such that a fragment of the proper size can be removed.
- the amylin-encoding sequence was deleted from the exon 3 -containing DNA sequence by re- striction enzyme digestion. The selected marker sequence was then inserted in its place.
- the marker sequence can be any nucleic acid sequence which is detectable and/or assayable, however typically it is an antibiotic resistance gene or other sequence whose expression or presence in the genome can easily be detected.
- the marker sequence is usually opera- bly linked to its own promoter or to another strong promotor from any source which will be active or which can easily be activated in the cell into which it is inserted.
- the marker sequence need not, however, have its own promotor attached as it may be transcribed using the promotor of the amylin gene.
- the marker sequence will normally have a polyA sequence attached to the 3' end, which serves to terminate transcription.
- Preferred marker genes are any antibiotic resistance genes such as neo
- neomycin resistance gene or genes coding for an enzyme having detectable activity such as beta-gal (beta-galacto- sidase) .
- the marker sequence is ligated in to the genomic DNA sequence using methods known to those skilled in the art and described in Sambrook et al . supra .
- the ends of the DNA fragments to be ligated must be compatible; this is achieved by either cutting all fragments with enzymes which generate compatible ends, or by blunting the ends prior to ligation (for example by the use of Klenow fragment to fill in sticky ends) .
- a knockout construct was constructed to include a phosphoglycerate kinase 1 promoter-driven neomycin resistance gene cassette as the marker sequence .
- the ligated knockout construct may then be inserted directly into embryonic stem cells, or it may be first be placed into a suitable vector for amplification prior to insertion.
- suitable vectors are those which are rapidly amplified in bacterial cells such as the pBluescript II SK vector (Stratagene, San Diego, CA) or pGEM7 (Promega Corp., Madison, WI) .
- This invention contemplates the production of knockout mammals, such as mammals from any species of rodent, including without limitation, rabbits, rats, hamsters, and mice.
- rodents include members of the Muridae family, which includes rats and mice.
- the embryonic stem cells used to produce the knock- out mammal will be of the same species as the knockout mammal to be generated.
- mouse embryonic stem cells will usually be used for generation of knockout mice.
- the use of embryonic stem cells from mice to generate amylin knockout mice is described in Example 2.
- Embryonic stem cells are typically selected for their ability to integrate into and become part of the germ line of a developing embryo so as to create germ line transmission of the knockout construct.
- any embry- onic stem cell line which is believed to have this capability is suitable for use herein.
- One mouse strain which is typically used for the production of embryonic stem cells is the 129J strain.
- a preferred embryonic stem cell line is murine cell line D3 (American Type Culture Collec- tion catalog no. CRL 1934) .
- the mouse 129SV embryonic stem cell line E14 was used in the experiments described in Example 2.
- the cells are cultured and prepared for DNA insertion using methods known in the art, such as those set forth by Robertson in: Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.J. Robertson ed. , IRL PRess, Washington, D.C. (1987); and by Hogan et al . , Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1986) . Insertion of the knockout construct into the embryonic stem cells can be accomplished using a variety of methods known in the art including, for example, electroporation, microinjection, and calcium phosphate treatment (see Lovell-Badge, in Robertson, ed. , supra) . A preferred method of insertion is electroporation, which was used in the experiments described in Example 2.
- each knockout construct DNA to be inserted into the cell is first linearized if the knockout construct has been inserted into a vector, which is accomplished by digesting the DNA with a suitable restriction endonuclease selected to cut only within the vector sequence and not within the knockout construct sequence.
- the knockout construct DNA is added to the embryonic stem cells under appropriate conditions for the insertion method chosen. If the cells are to be electroporated (see Example 2) , the embryonic stem cells and knockout construct DNA are exposed to an electric pulse using an electroporation machine and following the manufacturer's guidelines for use. After electroporation, the cells are allowed to recover under suitable incubation conditions. The cells are then screened for the presence of the knockout construct .
- Screening can be done using a variety of meth- ods .
- the marker sequence is an antibiotic resistance gene
- the cells are cultured in the presence of an otherwise lethal concentration of antibiotic. Those cells which survive have presumably integrated the knockout construct.
- recom- binant embryonic stem cells were evaluated for resistance to neomycin. If the marker sequence is other than an antibiotic resistance sequence, a Southern blot of the embryonic stem cell genomic DNA can be probed with a sequence of DNA designed to hybridize only to the marker sequence.
- the marker sequence is a gene which encodes an enzyme whose activity can be detected (for example, beta-galactosidase)
- the enzyme substrate can be added to the cells under suitable conditions, and the enzymatic activity can be analyzed.
- the knockout construct may be integrated into several locations in the embryonic stem cell genome, and may integrate into a different location in each cell's genome, due to the occurrence of random insertion events.
- the desired location of the insertion is in a complementa- ry position to the DNA sequence to be knocked out. Typically, less than about 1-5 percent of the embryonic stem cells which take up the knockout construct will actually integrate the knockout construct in the desired location.
- the DNA can be extracted from the cells using standard methods such as those described by Sambrook et al . , supra . As referenced in Example 2, the DNA can then be probed on a Southern blot with a probe or probes designed to hybridize in a specific pattern to genomic DNA digested with particular restriction enzyme (s). Alternatively or additionally, the genomic DNA can be amplified by PCR with probes specifically designed to amplify DNA fragments of a particular size and sequence (i.e. , only those cells which contain the knockout con- struct in the proper position will generate DNA fragments of the proper size) .
- Inser- tion may be accomplished in a variety of ways, however, a preferred method is by microinjection, as set forth in Example 2.
- microinjection about 10-30 cells are collected into a micropipet and injected into embryos in the proper stage of development to integrate the embryonic stem cell into the developing embryo.
- the suitable stage of development for the embryo is generally species depen- dent; for mice it is about 3.5 days.
- the embryos may then be obtained by perfusing the uterus of pregnant females . Suitable methods for accomplishing this are known in the art and are set forth by Bradley in Robertson, ed. , supra .
- the embryonic stem cell line carries the genes for white fur, the embryo selected will carry genes for black or brown fur.
- the embryo is implanted into the uterus of a pseudopregnant foster mother animal. While any foster mother animal may be used, they are typically selected for their ability to breed and reproduce well and for their ability to care for their young. Such foster mother animals are typically prepared by mating with vasectomized males of the same species. The stage of the pseudopregnant foster mother animal is important for successful impartation, and it is species dependent. For mice, this state is about 2-3 days.
- offspring which are born to the foster mother animal may be screened initially for mosaic coat color if the coat color selec- tion strategy has been employed.
- DNA from tail tissue of the offspring may be screened for the presence of the knockout construct using Southern blots and/or PCR.
- Offspring which appear to be mosaics are then crossed with each other if they are believed to carry the knockout construct in their germ line to generate homozygous knockout animals. If it is unclear whether the offspring will have germ line transmission, they can be crossed with a parental or other strain and the offspring screened for heterozygosity .
- the heterozygotes are identified by Southern blots and/or PCR amplification of the DNA. The heterozygotes can then be crossed with each other to generate homozygous knockout offspring. See Example 2.
- Homozygotes may be identified by Southern blotting of equivalent amounts of genomic DNA from animals which are known to be the product of the cross, as well as animals which are known heterozygotes and wild type animals .
- Northern blots can be used to probe the mRNA for the presence or absence of transcripts encoding either the amylin gene, the marker sequence or both.
- Western blots can be used to assess the level of expression of the gene knocked out in various tissues of these offspring by probing the Western blot with an antibody against amylin, or an antibody against the marker sequence product.
- in situ analysis such as fixing the cells and labelling with antibody
- fluorescence activated cell sorting (FACS) analysis of various cells from the offspring can be conducted using suitable antibodies to look for the presence or absence of amylin.
- FACS fluorescence activated cell sorting
- mice prepared and bred as described herein lack a functional amylin gene, as confirmed by studies showing the absence of immunoreactive amylin in the islets. The mice do, however, retain normal insulin levels. It was also discovered that the amylin knockout mice develop and reproduce normally. Furthermore, as described in Example 3, weight gain, food intake, fasting plasma levels of glucose, and basal insulin levels did not differ between the wild type and amylin knockout mice. Importantly, it was also surprisingly found that, at thirty minutes following an intravenous glucose challenge, knockout mice had an accelerated elimination of glucose, which was further accentuated during the challenge. See Example 3. Similarly, following a peroral glucose challenge (150 mg per animal) , glucose elimination was enhanced in knockout mice. No difference was seen in plasma insulin levels between amylin knockout mice and wild type mice in these experiments.
- amylin knockout mice are normoglycemic in the fed and fasted state.
- the mice clear glucose more efficiently in glucose tolerance tests.
- male amylin knockout mice show abnor- mal insulin levels during glucose tolerance tests, or after a 24 -hour fast.
- male amylin knockout mice develop obesity on a normal chow diet.
- aged amylin knockout mice, including obese males have 25-50% reduced fed plasma insulin levels compared to controls.
- amylin knockout mice react less to pain.
- amylin knockout mammals may be used to identify or evaluate amylin agonist molecules. Screening for useful compounds may include the steps of administering a candidate compound or compounds over a range of doses to the mammal, and assaying at various time points for the effects of the compound on the amylin function being evaluated. Such assays may include, for example, looking for increased or decreased levels of amylin activities, such as hyperglycemic or hyperlactemic activity or activity in the regulation of gastric emptying, or looking for increased or decreased levels of chemical messengers, such as cAMP.
- the mammals of the present invention are useful for evaluating the development of diabetes, the effects of loss of endogenous amylin protein activity, and for studying the effects of particular gene mutations, including the effects of the loss of amylin gene activity.
- FIGURE 1 A mouse amylin genomic sequence (LAMBDA M- amylin-14) shown in FIGURE 1 was isolated from a mouse Balb/c lambda FIXII library (Stratagene, San Diego, CA) using a human amylin cDNA probe corresponding to a 300 bp
- FIGURE 2 A 3.46 kbp Hindlll-Xbal fragment shown in FIGURE 2 was subcloned in plasmid pBluescript SK- (Stratagene, San Diego, CA) . This subclone (pHX) was further charac- terized and was shown to contain the amylin encoding sequence. This sequence was removed from pHX by deleting an 890-base pair sequence by restriction digestion with Sphl and BamHI (see FIGURE 3) .
- the deleted sequence was replaced by a phospho- glycerate kinase 1 promotor (PGK) -driven neomycin resistance gene cassette (PGK-neo) (Dr. J.K. Heath, Oxford) excised from its pBluescript SK-vector by Hindlll-Xhol , in a ligation reaction following blunt ending of the respective DNA ends by the Klenow fragment of DNA polymerase I.
- PGK phospho- glycerate kinase 1 promotor
- PGK-neo phospho- glycerate kinase 1 promotor
- PGK-neo phospho- glycerate kinase 1 promotor
- PGK-neo phospho- glycerate kinase 1 promotor
- PGK-neo phospho- glycerate kinase 1 promotor
- PGK-neo phospho- glycerate kinase 1 pro
- the p) am targeting construct was excised from the Bluescript vector with Xhol digestion (FIGURE 4) , purified by gel filtration and 50 Fg of the construct was electroporated into the mouse 129SV embryonic stem cell line E14 (Hooper et al . , Nature , 326:292-295 (1987)) using BioRad Gene Pulser equipment set at 260V, 500 FF. G418- resistant embryonic stem cell clones were selected, isolated, frozen and processed for Southern blot analysis as described in Leveen et al . , Genes & Development, 8:1875-1887 (1994).
- a 1.5 kilobase pair EcoRI-Hindlll genomic fragment (from pEII, see FIGURE 1) , flanking the targeting construct by the 5' end, was used to identify clones which had undergone homologous recombination at the amylin gene locus.
- a recombinant clone (clone 60), displaying a 3.5 kbp EcoRI fragment in addition to the wild type 12 kbp EcoRI fragment was thawed, cultured and injected into C57B6J mouse strain blastocysts as described in Leveen et al . , supra .
- Male chimeras were identified by virtue of their fur coat color and high degree chimeras were bred with C57B6J females.
- Mutant heterozygote offspring were identified by Southern blot analysis of DNA from tail biopsies. Heterozygous animals were crossed and mutant homozygotes (amylin gene knockout mice) were derived in agreement with Mendelian allele transmission. The absence of amylin-encoding genomic sequences in the amylin gene knockout mice was confirmed by Southern blot analysis using an amylin gene exon 3 -specific probe. The results showed a reduced signal in the +/- compared with the +/+ DNA and absence of signal in the -/- DNA.
- Amylin knockout mice obtained by the methods described in Examples 1 and 2 and control (wild type) mice were subjected to intravenous and oral glucose challenge tests.
- intravenous challenge test 1 g/kg glucose was administered intravenously and the plasma glucose measured over time.
- peripheral glucose challenge test 150 mg/animal glucose was administered orally and the plasma glucose measured over time.
- mice 12-week-old mice were fasted for 24 hours, anaesthetized and given 150 mg/animal glucose orally.
- IVGTT groups of age- and sex-matched 8-12-week-old mice were anaesthetized and given 1 g/kg glucose into the tail vein without prior fasting, and the plasma glucose measured over time.
- Glucose and insulin concentrations in plasma were measured over time using the glucose oxidase technique and a radioimmunoassay, respectively.
Abstract
Cette invention se rapporte à des animaux non humains transgéniques, tels que des souris, dont on a supprimé l'activité des gènes d'amyline, et à des utilisations de ces animaux.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU35687/97A AU3568797A (en) | 1996-06-07 | 1997-06-06 | Transgenic mammals lacking expression of amylin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66013496A | 1996-06-07 | 1996-06-07 | |
US08/660,134 | 1996-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997046669A1 WO1997046669A1 (fr) | 1997-12-11 |
WO1997046669A9 true WO1997046669A9 (fr) | 1998-04-23 |
Family
ID=24648296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/009887 WO1997046669A1 (fr) | 1996-06-07 | 1997-06-06 | Mammiferes transgeniques avec suppression de l'expression de l'amyline |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3568797A (fr) |
WO (1) | WO1997046669A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207877B1 (en) | 1998-09-23 | 2001-03-27 | Aventis Behring Gmbh | Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding |
ES2318880T3 (es) * | 1998-09-23 | 2009-05-01 | Csl Behring Gmbh | Un animal transgenico defectuoso para el factor xiii de la coagulacion y su uso para prbar la cicatrizacion de herida y la hemorragia. |
EP1045026A1 (fr) * | 1999-04-16 | 2000-10-18 | Aventis Behring Gesellschaft mit beschränkter Haftung | Animal transgenique comportant un gène de facteur XIII déficient et utilisation dudit animal pour tester la cicatrisation et l'hemorragie |
SE9901115D0 (sv) * | 1999-03-25 | 1999-03-25 | Pharmacia & Upjohn Ab | Nucleotide sequences |
-
1997
- 1997-06-06 AU AU35687/97A patent/AU3568797A/en not_active Abandoned
- 1997-06-06 WO PCT/US1997/009887 patent/WO1997046669A1/fr active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ishii et al. | Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet‐activating factor receptor | |
Behringer et al. | Dwarf mice produced by genetic ablation of growth hormone-expressing cells. | |
JP5185962B2 (ja) | エネルギー恒常性および細胞小器官代謝の調節に関与するMnkキナーゼ相同性タンパク質 | |
JPH10108587A (ja) | ひとインシュリン遺伝子を含むトランスジェニック・マウス | |
Muff et al. | Biological importance of the peptides of the calcitonin family as revealed by disruption and transfer of corresponding genes | |
US6127598A (en) | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity | |
US6071697A (en) | Method for testing the differentiation status in pancreatic cells of a mammal | |
Giridharan | Animal models of obesity & their usefulness in molecular approach to obesity | |
JP2004510960A (ja) | 肥満および糖尿病におけるインスリン抵抗性を治療する方法 | |
WO1997046669A9 (fr) | Mammiferes transgeniques avec suppression de l'expression de l'amyline | |
Wei et al. | Effect of chronic hyperghrelinemia on ingestive action of ghrelin | |
WO1997046669A1 (fr) | Mammiferes transgeniques avec suppression de l'expression de l'amyline | |
US20110265194A1 (en) | Them5-modified models of non-alcoholic fatty liver disease | |
Herberg et al. | Obesity/diabetes in mice with mutations in the leptin or leptin receptor genes | |
WO1997042309A1 (fr) | ANIMAUX TRANSGENIQUES PRESENTANT UNE DEFICIENCE EN RECEPTEUR β3-ADRENERGIQUE ENDOGENE ET LEURS UTILISATIONS | |
JP2003530066A (ja) | ヒトニューロゲニン3をコードするヌクレオチド配列 | |
US6486380B1 (en) | Pancreatic β cell hexokinase transgene | |
AU730141B2 (en) | Transgenic animals with disrupted npy y1 receptor genes | |
US6080911A (en) | Mice models of growth hormone insensitivity | |
Kahn | The Gordon Wilson Lecture. Lessons about the control of glucose homeostasis and the pathogenesis of diabetes from knockout mice. | |
JP2003512852A (ja) | インスリン非依存性糖尿病のコンジェニック動物モデル | |
US5948623A (en) | Method for testing the differentiation status in pancreatic cells of a mammal | |
Bosch et al. | Transgenic mice in the analysis of metabolic regulation | |
Chua Jr et al. | Obesity/diabetes in mice with mutations in leptin or leptin receptor genes | |
Fukamizu | Transgenic animals in endocrinological investigation |